Skip to main content
SpringerLink
Log in

Entresto (Sacubitril/Valsartan): Angiotensin Receptor Neprilysin Inhibition for Treating Heart Failure

  • Heart Failure (F Peacock and L Zhang, Section Editors)
  • Published:
Current Emergency and Hospital Medicine Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Heart failure is a major and growing public health problem throughout the world. Sacubitril/valsartan is a new medication with proven benefit in chronic heart failure with reduced ejection fraction. In order to use it most effectively, a thorough understanding of this medication is essential for providers.

Recent Findings

Recent evidence demonstrates a significant improvement in mortality and heart failure hospitalizations and an acceptable side effect profile with sacubitril/valsartan in patients with heart failure and reduced ejection fraction. The most frequent adverse reaction is hypotension, which rarely necessitates discontinuation of therapy. Trials are underway for additional indications for this medication.

Summary

Sacubitril/valsartan is a safe and efficacious treatment for heart failure with reduced ejection fraction. Whether use of sacubitril/valsartan in heart failure with preserved ejection fraction and in post-myocardial infarction left ventricular dysfunction will improve outcomes will be determined by ongoing studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017; doi:10.1161/CIR.0000000000000485.

    Google Scholar 

  2. Storrow AB, Jenkins CA, Self WH, Alexander PT, Barrett TW, Han JH, et al. The burden of acute heart failure on U.S. emergency departments. JACC Heart Fail. 2014;2:269–77. doi:10.1016/j.jchf.2014.01.006.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Blecker S, Ladapo JA, Doran KM, Goldfeld KS, Katz S. Emergency department visits for heart failure and subsequent hospitalization or observation unit admission. Am Heart J. 2014;168:901–8.e1. doi:10.1016/j.ahj.2014.08.002.

    Article  PubMed  PubMed Central  Google Scholar 

  4. •• McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. doi:10.1056/NEJMoa1409077. Large outcomes trial of sacubitril/valsartan in heart failure with reduced ejection fraction. Provides data on efficacy, safety and observed side effects.

    Article  PubMed  Google Scholar 

  5. Erdös EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J. 1989;3:145–51.

    PubMed  Google Scholar 

  6. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50:2357–68. doi:10.1016/j.jacc.2007.09.021.

    Article  CAS  PubMed  Google Scholar 

  7. Cruden NL, Fox KA, Ludlam CA, Johnston NR, Newby DE. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension. 2004;44:913–8. doi:10.1161/01.HYP.0000146483.78994.56.

    Article  CAS  PubMed  Google Scholar 

  8. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI40–8.

    CAS  PubMed  Google Scholar 

  9. • Bayés-Genís A, Barallat J, Galán A, de Antonio M, Domingo M, Zamora E, et al. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015;65:657–65. doi:10.1016/j.jacc.2014.11.048. Provides physiologic rational for therapeutic neprilysin inhibition in heart failure.

    Article  PubMed  Google Scholar 

  10. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998;135:825–32.

    Article  CAS  PubMed  Google Scholar 

  11. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–7. doi:10.1056/NEJMoa020233.

    Article  CAS  PubMed  Google Scholar 

  12. Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948–54. doi:10.1016/j.amjcard.2004.12.032.

    Article  CAS  PubMed  Google Scholar 

  13. Maisel A, Hollander JE, Guss D, McCullough P, Nowak R, Green G, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004;44:1328–3. doi:10.1016/j.jacc.2004.06.015.

    Article  PubMed  Google Scholar 

  14. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635–41. doi:10.1016/j.jacc.2003.09.044.

    Article  CAS  PubMed  Google Scholar 

  15. Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168–74. doi:10.1161/01.CIR.0000144310.04433.BE.

    Article  CAS  PubMed  Google Scholar 

  16. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107:1278–83.

    Article  CAS  PubMed  Google Scholar 

  17. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension. 1995;25:227–34.

    Article  CAS  PubMed  Google Scholar 

  18. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A. 2000;97(8):4239–44. doi:10.1073/pnas.070371497.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Horio T, Tokudome T, Maki T, Yoshihara F, Suga S, Nishikimi T, et al. Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology. 2003;144:2279–84.

    Article  CAS  PubMed  Google Scholar 

  20. Ando S, Rahman MA, Butler GC, Senn BL, Floras JS. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension. 1995;26:1160–6.

    Article  CAS  PubMed  Google Scholar 

  21. McDowell G, Nicholls DP. The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man. Expert Opin Investig Drugs. 1999;8:79–84. doi:10.1517/13543784.8.1.79.

    Article  CAS  PubMed  Google Scholar 

  22. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356:615–20.

    Article  CAS  PubMed  Google Scholar 

  23. Blais C, Fortin D, Rouleau JL, Molinaro G, Adam A. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts. J Pharmacol Exp Ther. 2000;295:621–6.

    CAS  PubMed  Google Scholar 

  24. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920–6.

    Article  CAS  PubMed  Google Scholar 

  25. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255–66. doi:10.1016/S0140-6736(09)61966-8.

    Article  CAS  PubMed  Google Scholar 

  26. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15:1062–73. doi:10.1093/eurjhf/hft052.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325:293–302. Doi:10.1056/NEJM199108013250501.

  28. Gaziano TA, Fonarow GC, Claggett B, Chan WW, Deschaseaux-Voinet C, Turner SJ, et al. Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol. 2016;1:666–72. doi:10.1001/jamacardio.2016.1747.

    Article  PubMed  Google Scholar 

  29. • Fonarow GC, Hernandez AF, Solomon SD, Yancy CW. Potential mortality reduction with optimal implementation of angiotensin receptor neprilysin inhibitor therapy in heart failure. JAMA Cardiol. 2016;1:714–7. doi:10.1001/jamacardio.2016.1724. This article highlights the potential benefit sacubitril/valsartan could provide if this medication was optimally implemented in patients who are candidates for this therapy.

    Article  PubMed  Google Scholar 

  30. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;68:1476–88. doi:10.1016/j.jacc.2016.05.011.

    Article  PubMed  Google Scholar 

  31. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;2016(37):2129–200. doi:10.1093/eurheartj/ehw128.

    Article  Google Scholar 

  32. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9. doi:10.1056/NEJMoa052256.

    Article  CAS  PubMed  Google Scholar 

  33. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol. 2007;50:768–77. doi:10.1016/j.jacc.2007.04.064.

    Article  PubMed  Google Scholar 

  34. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–95. doi:10.1016/S0140-6736(12)61227-6.

    Article  CAS  PubMed  Google Scholar 

  35. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med. 1992;327:669–77. doi:10.1056/NEJM199209033271001.

    Article  CAS  PubMed  Google Scholar 

  36. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–906. doi:10.1056/NEJMoa032292.

    Article  CAS  PubMed  Google Scholar 

  37. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995; 345:669–85.

  38. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet. 1994; 343:1115–22.

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Medicine, Altman Clinical and Translational Research Institute (ACTRI), University of California, San Diego, 9452 Medical Center Drive, La Jolla, CA, 92037, USA

    Nicholas Phreaner & Barry H. Greenberg

Authors
  1. Nicholas Phreaner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barry H. Greenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barry H. Greenberg.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest. Dr. Greenberg has been a consultant for Novartis and is a member of their speakers bureau.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Heart Failure

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Phreaner, N., Greenberg, B.H. Entresto (Sacubitril/Valsartan): Angiotensin Receptor Neprilysin Inhibition for Treating Heart Failure. Curr Emerg Hosp Med Rep 5, 47–55 (2017). https://doi.org/10.1007/s40138-017-0137-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40138-017-0137-2

Keywords

Search

Navigation